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Abstract
Pituitary adenomas are neoplasms of the anterior pituitary lobe and account for 15–20% of all intracranial tumors. Although
most pituitary tumors are benign they can cause severe symptoms related to tumor size as well as hypopituitarism and/or
hypersecretion of one or more pituitary hormones. Most pituitary adenomas are sporadic, but it has been estimated that 5%
of patients have a familial background. Germline mutations of the tumor suppressor gene aryl hydrocarbon receptor-
interacting protein (AIP) predispose to hereditary pituitary neoplasia. Recently, it has been demonstrated that AIP mutations
predispose to pituitary tumorigenesis through defective inhibitory GTP binding protein (Gai) signaling. This finding
prompted us to examine whether germline loss-of-function mutations in inhibitory guanine nucleotide (GTP) binding protein
alpha (GNAI) loci are involved in genetic predisposition of pituitary tumors. To our knowledge, this is the first time GNAI
genes are sequenced in order to examine the occurrence of inactivating germline mutations. Thus far, only somatic gain-of-
function hot-spot mutations have been studied in these loci. Here, we have analyzed the coding regions of GNAI1, GNAI2,
and GNAI3 in a set of young sporadic somatotropinoma patients (n= 32; mean age of diagnosis 32 years) and familial index
cases (n= 14), thus in patients with a disease phenotype similar to that observed in AIP mutation carriers. In addition,
expression of Gai proteins was studied in human growth hormone (GH), prolactin (PRL), adrenocorticotropic hormone
(ACTH)-secreting and non-functional pituitary tumors. No pathogenic germline mutations affecting the Gai proteins were
detected. The result suggests that loss-of-function mutations of GNAI loci are rare or nonexistent in familial pituitary
adenomas.
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Introduction
Pituitary adenomas are neoplasms of the anterior pituitary lobe.
They account for 15–20% of all the intracranial tumors [1] and
approximately 16% of all the primary brain and central nervous
system tumors [2]. The hallmarks of pituitary tumors are
hormonal dysfunction, i.e hormonal hypersecretion or hypopitu-
itarism and local symptoms related to the tumor mass. Compres-
sion of neighboring structures may cause headaches and visual
impairment [3]. Pituitary adenomas are classified based on the
pituitary cell of origin and the type of hormone secreted. The most
common functional pituitary tumors hypersecrete prolactin (PRL)
(40–45%). Patients with prolactinomas present with amenorrhea,
infertility and galactorrhea in females, and infertility in males.
Somatotropinomas hypersecrete growth hormone (GH) (20–25%),
causing acromegaly with clinical features of enlarged extremities,
coarse facial structures and comorbidities such as hypertension,
cardiovascular disease and diabetes mellitus [4]. The rate of
mortality associated to untreated acromegaly has been reported to
be two to four times higher than that seen in the healthy
population [5,6]. In many cases, slow progression of the symptoms
delays the diagnosis [7]. Somatotropinoma during childhood or
adolescence, before the growth of the long bones is complete, leads
to gigantism. Tumors secreting adrenocorticotropic hormone
(ACTH) (10–12%) cause Cushing’s disease, which is characterized
by hypercortisolism. The majority of the other adenomas are non-
functioning (non-secreting) pituitary adenomas (NFPA) [4]. All in
all, pituitary adenomas cause a heavy clinical burden due to
increased morbidity and the treatment modalities involved, i.e
neurosurgery, chronic medical therapies and radiotherapy.
Most pituitary adenomas are sporadic but it has been estimated
that 5% of affected patients have a familial background [8].
Pituitary adenomas occur as components of familial tumor
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syndromes such as multiple endocrine neoplasia type 1 (MEN1)
[9,10], Carney’s complex (CNC) [11,12] and MEN4 [13].
Furthermore, in 2006, Vierimaa et al. found that germline
mutations in the aryl hydrocarbon receptor interacting protein
(AIP) gene cause pituitary adenoma predisposition (PAP) [14].
AIP mutations are mostly associated with somatotropinomas
(78%), although cases with prolactinomas, NFPAs and Cushing’s
syndrome have also been reported [15,16]. The patients with AIP
mutations are typically young (mean age at diagnosis 25 years) and
do not necessary have a strong family history of the disease. AIP
associated pituitary tumors are often large and invasive and
resistant to the effects of available treatments, such as somatostatin
analogues, which are used in acromegaly [17–19]. Familial
occurrence of pituitary tumors is also the main feature in familial
isolated pituitary adenoma (FIPA) [8,20]. Subsequently, it was
found that AIP germline mutations explain 15–20% of FIPA
families and 50% of families with isolated familial somatotropino-
mas (IFS) [15]. Thus, the majority of FIPA families appear to be
influenced by some other, as yet unidentified genes responsible for
familiar clustering of pituitary tumors. Identification of new
predisposing genes would enable earlier detection of pituitary
adenomas and contribute to clinical management of patients.
The stimulatory guanine nucleotide (GTP) binding protein
alpha (GNAS; encoding Gas subunit) has been found to be
mutated in 30–40% of sporadic somatotropinomas. These somatic
gain-of-function mutations lead to constitutive activation of cyclic
adenosine monophosphate (cAMP) synthesis and increased
proliferation through cAMP mediated mitogenic signaling [21–
24]. Activating mutations on GNAS are also associated to
McCune-Albright syndrome [25,26]. Along with well-established
GNAS mutations, somatic mutations in other Ga family members,
namely GNAQ and GNA11, have been linked to tumorigenesis in
melanocytic neoplasms [27,28].
We have recently demonstrated that AIP loss-of-function
mutations predispose to pituitary tumorigenesis through defective
inhibitory GTP binding protein (Gai) signaling and consequent
elevated intracellular cAMP concentrations [29]. We found that
Gai-2 and Gai-3 proteins are not capable of inhibiting cAMP
synthesis during AIP deficiency and that Gai-2 protein levels are
significantly reduced in AIP-mutated somatotropinomas. As the
AIP protein seems to be an essential regulator of Gai signaling, the
possibility that inactivating germline mutations in GNAI loci
(encoding Gai subunits) would predispose to pituitary adenomas
prompted us to investigate the role of these genes in pituitary
tumorigenesis. Here we sequenced all the coding exons of GNAI1,
GNAI2 and GNAI3 in a set of young sporadic somatotropinoma
patients and familial index cases, thus in patients with a disease
phenotype similar to that observed in AIP mutation carriers.
Materials and Methods
Gai immunohistochemistry
To investigate the expression of Gai proteins in human pituitary
tumors, Gai-1, Gai-2 and Gai-3 immunostainings were performed
in four prolocatinomas, six somatotropinomas, three ACTH and
four NFPA tumors. All tumors were AIP mutation negative.
Antibodies used were mouse monoclonal antibody against Gai-1
(SPM397, sc-56536, Santa Cruz, 1: 40), rabbit polyclonal antibody
against Gai-2 (T19, sc-7276, Santa Cruz, 1: 60) and mouse
polyclonal antibody against Gai-3 (H00002773-B01P, Abnova
Corp. Taipei city, Taiwan, 1: 50). Anti-mouse/rabbit/rat second-
ary antibody, Poly-HRP-GAM/R/R (DPVB55HRP, Immuno-
logic, Duiven, Netherlands) and DAB chromogen (Lab Vision
Corporation, Fremont, CA, USA, Thermo Fisher Scientific,
Watham, MA, USA) were used for detection. Immunostaining
protocol was applied as described [30]. The staining intensities of
Gai proteins were scaled as negative (0), weak (1), moderate (2), or
strong (3). The images were taken and edited by Leica DM LB
microscope (Meyer Instruments, Houston, TX, USA), Olympus
DP50 camera (Olympus Corporation, Tokyo, Japan) and Studio
Lite software (Licor, Lincoln, NE, USA).
Patients
This study included a set of 32 young sporadic GH-secreting
pituitary adenoma cases in which three of the tumors were
secreting both GH and PRL. Age at diagnosis for sporadic cases
ranged from 14 to 56 years with a mean of 32 years (Table 1). A
majority of the tumors were macroadenomas. The second set of
samples included 14 index cases with a familial history of pituitary
adenomas (Table 1). The hormones secreted by the tumors were
GH (n=11), PRL (n=1), ACTH (n=1) and NFPA (n=1). All the
patients had previously been sequenced negative for AIP. From
familial cases 9/14 were earlier screened negative for large
germline deletions of AIP [31]. The study and the consent
procedures were approved by the Ethics Committee of the
Hospital district of Helsinki and Uusimaa (HUS) (approval
number: 408/13/03/03/2009) and the Institutional Review
Board of the Department of Internal Medicine, General Hospital,
Montebelluna (Treviso). Signed informed consent was obtained
from all the study participants. In case of the minor/children, the
consent was obtained from parent/guardian. Consents are stored
and managed together with patient information in the central
office/ambulatories where the access is restricted.
Mutation Analysis on GNAI loci
The coding regions of GNAI1 (ENST00000442586 and
ENST00000351004; Ensemble release 75), GNAI2 (ENST
00000422163, ENST00000451956 and ENST00000266027),
and GNAI3 (ENST00000369851) were amplified and sequenced
from blood-derived DNA. Also intronic regions flanking the exons
were included in the analyses. PCR was carried out by mixing
0.25 ml 20 mM of each primers (Table 2), 5 ng/ul of DNA, 0.4 ml
40 mM of dNTP, 2.5 ml 10xPCR Buffer, and 0.1 ml AmpliTaq
Gold DNA Polymerase (Invitrogen Life Science Technologies,
Foster City, CA) in a final volume of 25 ml. PCR products were
purified by using ExoSAP-IT PCR product cleanup reaction
(Affymetrix, USB Products, CA, USA). DNA was sequenced by
using BigDye v.3.1 sequencing chemistry and ABI3830x DNA
sequencer (Applied Biosystems, Foster City, CA, USA). Sequences
were analyzed with Mutation Surveyor software V4.0.8 (Soft-
Genetics, State College, PA, USA).
Results
Gai immunohistochemistry
To examine the Gai protein expressions in human pituitary
adenomas, Gai-1, Gai-2, Gai-3 expressions were immunohisto-
chemically (IHC) analyzed in AIP mutation negative somatotro-
pinomas, prolactinomas, NFPA and ACTH tumors. Weak and
speckled cytoplasmic expression of Gai-1 was detected in GH-
(mean6SD; 0.860.4) and PRL- (160.8) secreting tumors,
whereas NFPA (1.860.5) and ACTH (1.760.6) tumors showed
weak to moderate cytoplasmic expression (Figure 1). Consistent
with the earlier observation in human GH-secreting tumors [29],
Gai-2 was prominently expressed in the cytoplasm of the
somatotropinomas (2.860.4). Prolactinomas displayed moderate
to strong expression of Gai-2 (2.560.6). NFPA (1.860.5) and
ACTH (1.760.6) adenomas showed moderate cytoplasmic and
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Table 2. Primer sequences, annealing temperatures and Ensembl transcripts for 23 amplicons of GNAI loci.
Primer Sequence (59 –39) Tm (6C) Trancript
Gai1_ex1_F GGATTCCCCTGTGCTTGGA 60 ENST00000442586
Gai1_ex1_R GTTTCCAAACGCCGAGGG
Gai1_ex2&3_F CACACAGAGAGAGACTGGGTG 60 ENST00000351004
Gai1_ex2&3_R GGTCCTGATAGTTGACAAGCC
Gai1_ex4_F AAGGAAGTTCGCTATTGCC 60 ENST00000351004
Gai1_ex4_R AATGTGTCAGCCAATTCTGC
Gai1_ex5_F GTTTTGGATGATCTTTATTGGC 60 ENST00000351004
Gai1_ex5_R TCTCCCAAACATTCTTTTGTCC
Gai1_ex6_F CCCATAAAGTCCTTCTCTCCTTC 6261, 6161, 6062, 5962,5862 ENST00000351004
Gai1_ex6_R CTTGGCAACACCTTCAGCTC
Gai1_ex7_F TGTTCTGAAATGGCAGAAATG 60 ENST00000351004
Gai1_ex7_R CTGAATTCTTGCCTTAGGGG
Gai1_ex8_F GGAGTCCATGAATGAAACTGTATG 60 ENST00000351004
Gai1_ex8_R TTTGGTCAAGTCCCAGATGC
Gai2_ex1c_F TCACCCACATCACCGTCTAA 59 ENST00000422163
Gai2_ex1c_R ACGCGTCCTCTTGCAACTA
Gai2_ex1d_F CGCTGTCCATTGCTCTTCAT 60 ENST00000451956
Gai2_ex1d_R GCACATGTGAGCATTCAGGT
Gai2_ex2_F AGCTGAAGTGTGACGCTGTG 58 ENST00000266027
Gai2_ex2_R CTTGGCCAGCCATGAAGG
Gai2_ex3&4_F ATGTGAGAACAGGGTGGCTC 58 ENST00000266027
Gai2_ex3&4_R GGATTCCCTAGGATGAGACTTG
Gai2_ex5_F CCAAGAATACCCTAGCCTGG 60 ENST00000266027
Gai2_ex5_R GCAAAGACCAGCAGTGTCC
Gai2_ex6_F CTACCTGAACGACCTGGAGCGTA 58 ENST00000266027
Gai2_ex6_R CTCTGCTACCCCAGAGGCTG
Gai2_ex7&8_F AAATGGGGTAGAAAGCCTCC 58 ENST00000266027
Gai2_ex7&8_R TGGTCACCATAGGCTACTTGG
Gai2_ex9_F CTTGCTGCACACGTAGGATG 58 ENST00000266027
Gai2_ex9_R CGCTTAGTTCTTCCCCAGC
Gai2_ex9b_F GTCCACCTGCTCATTCTCGT 60 ENST00000266027
Gai2_ex9b_R TGGAACCCAATTCTGTGGAG
Gai3_ex1_F GCAGTTTCCGTGGTGTGAG 58 ENST00000369851
Gai3_ex1_R GTTCAGGCCTTCCAAGCG
Gai3_ex2&3_F TAGGACCCGTGGTTTTCATC 60 ENST00000369851
Gai3_ex2&3_R TTGTTGCTTAAATTCATTTCCC
Gai3_ex4_F CTGGCCTGTCAGAAAAGGTC 60 ENST00000369851
Gai3_ex4_R AAACATTTCCTTAAGTGGGGAC
Gai3_ex5_F TTTGCTATGCACATGGTTGG 60 ENST00000369851
Gai3_ex5_R AAATTTTACCCTGATTAAGAGATGG
Gai3_ex6_F CATTTCAGTTTAGGGGAAGGTG 60 ENST00000369851
Gai3_ex6_R TTATTTTCCATTTCCTGGCTAC
Gai3_ex7_F TGAATGCCATTTAGTGCTGC 60 ENST00000369851
Gai3_ex7_R GCCACTACCACTGAATACTCTCC
Gai3_ex8_F TTGGGTTATGTTCCCTCTCC 60 ENST00000369851
Gai3_ex8_R CAAGAGACATCACTGTAGCACTATAAC
Tm: annealing temperature.
doi:10.1371/journal.pone.0109897.t002
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occasional nuclear Gai-2 staining. All tumor types displayed
moderate cytoplasmic expression of Gai-3 (GH: 2.360.5, PRL:
260.8, ACTH: 1.660.6, NFPA: 1.860.5). Weak to moderate
nuclear Gai-3 staining was also observed in all tumor types (GH:
1.360.8, PRL: 0.860.5, ACTH: 1.360.6, NFPA: 1.560.6).
GNAI loci mutation analysis
All the GNAI coding exons (23 amplicons per sample) were
successfully sequenced and analyzed in 32 young sporadic
somatotropinoma and 14 index familial cases (Table 1). In
GNAI1, earlier reported synonymous heterozygous variations
were detected in exon 6 (rs12721456/5 samples) and in exon 7
(rs10241877/8 samples). In GNAI2, one reported heterozygous
and synonymous variation was found in exon 4 (rs762707/3
samples). Also in GNAI3, only previously observed heterozygous
synonymous variations were detected in exon 1 (rs2230350/3
samples) and exon 8 (rs61758987/1 sample). None of these
variants modified amino acid sequence, indicating the polymor-
phic nature of these changes. Additionally, several reported and
unreported variations were observed in intronic regions (Table
S1). All the intronic variants located outside of the splice site
consensus sequences and are thus not assumed to affect splicing
events.
Discussion
Many G proteins have been linked to tumor development,
starting with the discovery that somatic gain-of-function mutations
of codons 201 and 227 in the GNAS gene are responsible in one
third of the sporadic somatotropinomas with elevated cAMP levels
[23,32]. Activating GNAS hot-spot mutations have been detected
in many other tumor types. For instance, biliary tract, thyroid,
pancreatic, colon, and testis tumors are common targets of somatic
GNAS mutations. Additionally, activating somatic hotspot muta-
tions have been reported in GNAQ (Gaq) and GNA11 (Ga11)
genes in melanomas and meningeal tumors [33]. Somatic
mutations in other Ga subunit genes have been detected, albeit
in a low frequency.
Proteins of the inhibitory Ga subfamily, Gai/Gao, mediate
several cellular and metabolic functions [34–37]. Unlike the Gao,
Gai-1, Gai-2 and Gai-3 subunits are involved in the hormonal
inhibition of adenylate cyclase (AC) activity with subsequent
decrease of intracellular cAMP levels [38,39]. Previous studies
have been focusing on screening GNAI2 somatic hot-spot
mutations (termed gip2 oncogene) in codons 179 and 205.
Somatic gip2 mutations have been found in ovarian, adrenal,
ACTH and NFPA tumors [32,40,41]. However, other studies
have failed to confirm these initial findings [42–48]. Although
isolated somatic mutations of GNAI genes have also been observed
in next-generation sequencing efforts, further experiments are
needed to validate the existence and relevance of these findings
[49,50].
In our original study, we found that AIP deficiency is associated
in pituitary tumorigenesis via reduced Gai signaling followed by
elevated cAMP concentrations [29]. In the current study, we
searched for germline mutations in GNAI loci in pituitary
adenoma patients compatible with the AIP phenotype; young
patients with somatotropinoma and familial index cases (Table 1).
Also protein expressions of Gai-1, Gai-2 and Gai-3 were examined
in human GH-, PRL-, ACTH- and non-secreting (NFPA)
pituitary adenomas. We have earlier shown that Gai-2 and Gai-3
proteins are expressed in human somatotropinomas [29]. Here we
observed that also the Gai-1 protein, although at low levels, is
present in GH-secreting pituitary adenomas. Moreover, immuno-
reactions against all three Gai proteins were detected in human
prolactinomas, ACTH and NFPA tumors (Figure 1), suggesting a
biological role of all these proteins in these tumor types as well.
We screened for germline mutations in the GNAI loci in
sporadic somatotropinoma patients (n=32) and familial index
cases (n=14) characterized by the AIP phenotype (Table 1). No
pathogenic mutations were observed in any of the patients studied.
All the detected variants were either known polymorphisms or
located in intronic regions. Although certain intronic variants may
Figure 1. Gai-1, Gai-2, and Gai-3 protein expressions in GH, PRL, ACTH and non-functioning (NFPA) pituitary adenomas. Scale
bar = 20 mm.
doi:10.1371/journal.pone.0109897.g001
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cause impaired splicing, the observed variants were not proximal
to known splice sites. We acknowledge that the sample size in the
present study is insufficient to draw a definite conclusion of the
involvement of GNAI germline mutations in genetic predisposition
of pituitary tumors. Moreover, due to the small sample size there is
no adequate power to detect possible associations between the
observed variant alleles and a pituitary tumor phenotype.
To our knowledge, this is the first time that all the coding exons
of GNAI1, GNAI2 and GNAI3 have been sequenced to detect
germline loss-of-function mutations in a set of selected pituitary
adenoma patients. All in all, our sequencing results suggest that
germline mutations of the GNAI loci seem not to be associated to,
or are rare in familial pituitary tumorigenesis. However, a larger
set of samples, somatic mutation screenings, copy number profiling
and additional cellular works would provide a more comprehen-
sive result of the role of GNAI genes in pituitary tumorigenesis.
Supporting Information
Table S1 Intronic variations in GNAI loci.
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